




De novo variants in MED12 cause X-linked syndromic neurodevelopmental disorders 
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Purpose: MED12 is a subunit of the Mediator multiprotein complex with a central role in RNA 
polymerase II transcription and regulation of cell growth, development, and differentiation. 
This might underlie the variable phenotypes in males carrying missense variants in MED12, 
including X-linked recessive Ohdo-, Lujan-, and FG syndromes.  
Methods: By international matchmaking we assembled variant and clinical data on 18 
females presenting with variable neurodevelopmental disorders (NDDs) and harboring de 
novo variants in MED12.  
Results: Five nonsense variants clustered in the C-terminal region, two splice variants were 
found in the same exon 8 splice acceptor site, and 11 missense variants were distributed 
over the gene/protein. Protein truncating variants were associated with a severe, syndromic 
phenotype consisting of intellectual disability (ID), facial dysmorphism, short stature, skeletal 
abnormalities, feeding difficulties and variable other abnormalities. De novo missense 
variants were associated with a less specific, but homogeneous phenotype including severe 
ID, autistic features, limited speech and variable other anomalies, overlapping both with 
females with truncating variants as well as males with missense variants.  
Conclusion: We establish de novo truncating variants in MED12 as causative for a distinct 










MED12 is one of 31 subunits (MED1-MED31) of the large multiprotein Mediator 
complex that regulates gene expression in all eukaryotes by interacting with RNA 
polymerase II.1,2 It is involved in transcriptional elongation and termination, mRNA 
processing, noncoding RNA activation, super enhancer formation, and epigenetic 
regulation.2,3 Hence, Mediator complex is a master coordinator of cell growth and 
homeostasis, development, and differentiation,4 and its subunit MED12 is a critical 
transducer of regulatory information essential for organogenesis.5 MED12 consists of the 
Med12 domain that forms part of the kinase section of Mediator, which can negatively 
regulate the Gli3-dependent sonic hedgehog signaling pathway via its interaction with Gli3 
within RNA polymerase II,6 the Med12-LCEWAV domain, of which the function is not known, 
and the Med12-PQL domain that binds to β-catenin, which targets MED12 to activate 
transcription of Wnt-responsive genes.7 
Hemizygous missense variants in MED12 are known to cause at least three different 
but overlapping X-linked syndromic neurodevelopmental disorders (NDDs) in males: FG 
syndrome (FGS1, also known as Opitz-Kaveggia syndrome [OKS; OMIM 305450]), Lujan-
Fryns syndrome (LS; OMIM 309520), and X-linked Ohdo syndrome (OHDOX; OMIM 
300895). FGS1 is characterized by intellectual disability (ID), hypotonia, dysmorphic features 
such as macrocephaly, prominent forehead, downslanting palpebral fissures, small ears with 
occasionally sensorineural hearing loss, broad thumbs and halluces, constipation and/or anal 
anomalies, partial agenesis of the corpus callosum and characteristic hyperactive and 
talkative behavior.8,9 LS is characterized by mild to moderate ID, dysmorphic features such 
as macrocephaly, large head, a long thin face, low-set ears, prominent nasal bridge, high 
narrow palate, short and deep philtrum, tall stature with thin or marfanoid habitus, behavioral 
aspects and abnormalities of the corpus callosum.10,11 OHDOX is characterized by ID and 
typical facial features, including blepharophimosis, facial coarsening, thick alae nasi, and a 
triangular face.12,13 Additionally, variants in MED12 have been implicated in non-specific 





females with inherited MED12 variants,15,17,25 p.(Ser1967Glnfs*84), p.(Arg1148His) and 
p.(Ile771Thr), and three females with de novo MED12 variants,29–31 p.(Glu172Gln), c.1249-
1G>C and p.(Arg521His), were reported to have NDDs with variable cognitive impairment. 
Here, we report on assembled clinical and genetic data of 18 females with de novo 
variants in MED12. Truncating variants in seven individuals resulted in a syndromic 
presentation with variable ID, short stature, facial dysmorphism, feeding difficulties and 
skeletal abnormalities. Missense variants in 11 individuals were associated with a phenotype 
of severe ID, autistic features and limited speech and variable dysmorphic features. 
 
Materials and Methods 
DNA analysis and X-inactivation 
Affected individuals were referred by physicians working in disability services and 
clinical geneticists, and connected through personal communication, Decipher database32 
and GeneMatcher.33 MED12 variants were identified by exome or genome sequencing and 
confirmed by Sanger sequencing (Supplementary Table 1). X-chromosome inactivation 
(XCI) analysis was performed at the androgen receptor locus with a modification of the assay 
previously described.34 Primer sequences and PCR conditions for Sanger sequencing and 
XCI testing are available upon request. 
 
RNA Isolation, cDNA Synthesis and RT-PCR 
All RNA isolations were performed with the NucleoSpin RNA Clean-up Kit (cat. no. 
740955-50, Macherey-Nagel, Düren, Germany) according to manufacturer’s protocol. RNA 
was quantified by nanodrop. One microgram of total RNA was used for all cDNA synthesis 
reactions. For reverse transcription-PCR (RT-PCR) analysis, cDNA was synthesized by the 
SuperScript VILO Master Mix (cat. no. 11755050, Thermo Fisher Scientific, Waltham, MA, 





To determine the potential splice acceptor variant effect on MED12 splicing in 
individuals 6 and 7, RT-PCR analysis was performed using primers located in exon 8 
(forward) and exon 12 (reverse) of MED12. Primer sequences are available upon request. 
For RT-PCR analysis, 25 ng of cDNA was used for all reactions. Amplifications were 
performed according to standard procedures. PCR products were sequenced using the ABI 
PRISM BigDye Terminator Cycle Sequencing V2.0 Ready Reaction Kit and analyzed with 
the ABI PRISM 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA). 
 
Minigene-based splice assay 
The effect of the two splice acceptor variants was also assessed by minigene-based 
splicing assays employing wild-type and mutant constructs using DNA from individuals 6 and 
7 as a template. To amplify the genomic region encompassing exons 8 and 9 of the MED12 
gene, we designed PCR primers located in exons 7 (forward) and 11 (reverse) using 
Primer3plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). The PCR 
reaction mixtures of 50 μl contained 25 μM of each primer pair, a high-fidelity Taq 
polymerase Phusion® High-Fidelity DNA Polymerase (cat. no. M0530L, New England 
BioLabs, Ipswich, MA, USA), 5X PCR HF buffer, 1μl of dNTP mix, 5X Q solution and 5ng 
genomic DNA from patients 1 and 2. Amplifications were performed using a two-phase 
touchdown PCR program described before. The resulting PCR products were run on a 0.8% 
agarose gel and were purified with the NucleoSpin Gel and PCR cleanup kit (cat. no. 
740609.250; Macherey-Nagel, Düren, Germany), according to the manufacturer's protocol. 
One hundred fifty nanograms of each purified insert were cloned into the pDONR201 vector 
by using the Gateway BP Clonase Enzyme Mix (cat. no. 11789021; Thermo Fisher Scientific, 
Waltham, MA, USA). 
The different pDONR cloned constructs were validated by Sanger sequencing, and 
150 ng of each were cloned into the destination vector pCI-NEO-RHO exon3,5/DEST by 
using the Gateway LR Clonase enzyme mix (cat. no. 11791043; Thermo Fisher Scientific, 





two with the c.1249-1G>C and c.1249-2A>G variants. HEK293T cells (ATCC CRL-3216; 
American Type Culture Collection [ATCC], Wesel, Germany) were grown in DMEM 
supplemented with 10% (volume/volume) fetal calf serum (cat. no. F7524; Sigma Aldrich, St. 
Louis, MO, United States), 1% (volume/volume) Sodium pyruvate (cat. no. S8636; Sigma 
Aldrich, St. Louis, MO, United States), and penicillin/streptomycin (cat. no. P4333; Sigma 
Aldrich, St. Louis, MO, United States). Cells were seeded in 6-well plates at a density of 
5×105 cells/well and transfected the day after with 2 μg of each minigene using FuGENE HD 
Transfection Reagent (cat. no. E2311; Promega, Madison, WI, USA) with a DNA-to-liposome 
ratio of 1 μg:3 μl, according to the manufacturer's instructions. Medium was replaced after 24 
h, and cells were harvested 48 h after transfection. Total RNA isolation, cDNA production 
and RT-PCR reactions were performed as described before. The RT-PCR products were 
resolved on a 2% (weight/volume) agarose gel, the resulting bands were excised, and the 
nucleic acid was purified by using NucleoSpin Gel & PCR cleanup (cat. no. 740609.50, 
Macherey-Nagel, Düren, Germany). Sanger sequencing was performed on 100 ng of each 
purified band by using the same primers used in the PCR reaction showing no other variant 









Variant spectrum, splicing effects and X-inactivation 
Five individuals carried de novo nonsense variants in the last four exons and 
clustering in or down-stream of the catenin binding domain of MED12 (NM_005120.2) (Fig. 
1). In two individuals, de novo variants affecting the splice acceptor of exon 8 were identified: 
c.1249-1G>C and c.1249-2A>G. Additionally, 11 females carried de novo missense variants 
predicted to be deleterious (Supplementary Table 1). The identified missense variants were 
distributed over the N-terminal two thirds of the protein, and all but one were located between 
the LCEWAV and the catenin binding domain (Fig. 1). p.(Arg1138Trp) recurrently occurred in 
two individuals. None of the identified variants were present in the Genome Aggregation 
Database (gnomAD; https://gnomad.broadinstitute.org; Supplementary Table 1). The 
MED12 pLi score was 1 and the Z-score was 6.58, which indicates that there is strong 
selection against protein truncating variants and missense variants in males and females. 
We used RT-PCR to investigate whether the two variants in the canonical splice 
acceptor of exon 8 affected splicing. We found expression of only the wild-type fragment in 
EBV-LCL and fibroblast lines from individual 1 carrying the c.1249-1G>C variant, and in a 
fibroblast line from individual 2 who carried the c.1249-2A>G variant (Fig. 2B-C). To 
investigate the splicing defect in more detail, we generated two MED12 minigenes spanning 
exons 7 to 11 using control and patient genomic DNAs. HEK293T cells were transfected with 
mutant and control minigenes (Fig. 2D). While the control minigene did not show any splicing 
defect, both mutated minigenes showed complete skipping of exon 9 (Fig. 2E), leading to an 
abnormal transcript due to an early termination codon: p.(Val417Alafs*76). This indicates that 
the presence of only the wildtype allele in fibroblasts and EBV-LCLs might be due to either 
nonsense-mediated mRNA-decay or more likely skewing of XCI.  
Analysis of the X inactivation status showed extreme skewing (>95:5) in blood or 
fibroblasts of three individuals with protein truncating variants including individual 2, and 





receptor alleles were non-informative. In nine out of the 11 individuals with missense 
variants, XCI was extremely skewed (>95%) and skewed (85%) in one. In three individuals 
with a missense variant, XCI was random in peripheral blood cells. In four individuals where 
two different tissues, whole blood and either a fibroblast cell line or EBV-LCLs, were tested, 
XIC behaved comparable between tissues. Three of these individuals had skewing of X-
inactivation, and the variant was located on the inactive allele in the tested tissues.  
 
Clinical spectrum 
All seven individuals with de novo protein truncating variants in MED12 presented 
with ID, ranging from mild in one to severe/profound in four individuals (Table 1; 
Supplementary Table 1). Speech was commonly delayed, and absent in two individuals. 
Brain imaging by MRI or ultrasound was performed in five individuals and showed partial 
hypoplasia or agenesis of the corpus callosum and/or enlarged ventricles in three of them. 
Feeding difficulties were reported in five individuals, muscular hypotonia in four, autistic 
features in three, and seizures in only one individual. Birth weight and/or length below -2 SD 
were observed in two individuals as well as congenital microcephaly. Postnatally, short 
stature occurred in four of six individuals, of whom these data were available. The two 
individuals who were of normal length were the youngest of the six. This suggests that short 
stature is a progressive feature that might become apparent only at a later age. Microcephaly 
and macrocephaly were each reported once, whereas three individuals had a normal head 
circumference. Skeletal abnormalities were present in six out of the seven individuals and 
included syndactyly of fingers II-IV or of toes II and III as well as other finger anomalies, 
scoliosis or rhizomelic limb shortening. Facial gestalt was quite distinct in all the individuals 
and included sparse hair, low-set, posteriorly rotated ears, a prominent forehead or 
bitemporal narrowing, hypertelorism, downslanting palpebral fissures, blepharophimosis, 
palatal anomalies or a bifid uvula, dental crowding, and micro- or retrognathia (Fig. 3). 
Variable other features were laryngeal anomalies requiring tracheostoma in two individuals, 





1 and 2 with variants in the splice acceptor of exon 8 had less prominent micro/retrognathia 
and shared other clinical aspects such as a very prominent forehead with large fontanels, 
hypertelorism and MRI anomalies including partial agenesis of corpus callosum, enlarged 
ventricles and abnormal tectum and cerebellar vermis.  
In contrast, the individuals with de novo missense variants in MED12 presented with 
a less distinct, but still homogenous phenotype. Eight out of 11 individuals presented with 
severe to profound ID and six of those with absent speech. One exception was individual 14 
with a low-normal IQ of 83, but she had other hallmarks of MED12-related disorders, such as 
thin corpus callosum, a prominent forehead and ptosis. Behavioral abnormalities such as 
autistic features or attention deficit were common and reported in eight individuals. Corpus 
callosum anomalies were reported in four and cortical thinning in one of ten individuals in 
whom MRI was performed. Growth parameters were variable with mostly normal 
measurements at birth and postnatally. Short stature was reported in only one individual, 
while tall stature occurred in two individuals. Syndactyly of fingers or toes was reported in 
two individuals only, while scoliosis and pectus anomalies were reported in three individuals. 
Ophthalmological anomalies were found in nine individuals of which strabismus and 
nystagmus were most frequent. Further variable anomalies in single or few individuals 
included muscular hypotonia, hearing loss or constipation. Subtle and non-specific facial 










In this study, we identified 18 unrelated females with de novo variants in MED12 and 
presenting with variable NDDs. These cases can be classified into two molecularly and 
phenotypically distinct groups. Truncating variants were identified in seven individuals and 
resided either in the splice acceptor of exon 8 (n=2), resulting in out of frame skipping of 
exon 9, or clustered C-terminally in or downstream of the catenin binding domain (n=5). The 
phenotype of these individuals appeared rather distinct and comprised mainly severe ID, 
short stature, (severe) feeding difficulties, syndactyly of toes II and III and/or syndactyly of 
fingers II, III and IV and variable other skeletal abnormalities. Marked facial dysmorphism 
included an abnormal skull shape, sparse hair, low-set, posteriorly rotated ears, 
blepharophimosis, micro- and/or retrognathia and dental crowding. The presence of 
abnormal transcripts and subsequently truncated protein might be expected for these seven 
variants. Particularly for the C-terminal variant p.(Gln2150*), a truncating effect is likely since 
localization in the last or pen-ultimate exon usually does not lead to nonsense-mediated 
mRNA decay.35  
So far, pathogenic MED12 variants described in the literature have been mainly 
missense. Only two other truncating variants were reported previously. Firstly, a frameshift 
variant, c.5898dupC, also located in the C-terminal catenin-binding domain, was identified in 
10 affected males and an affected female from one family with severe to profound ID and 
facial dysmorphism.15 Nine carrier females showed only borderline to mild ID. This variant 
has been demonstrated to escape nonsense-mediated mRNA decay and lead to creation of 
an additional abnormal transcript due to activation of two cryptic splice sites in exon 41.15 
Secondly, a de novo splice variant that is identical to the one identified in individual 1 in this 
study, was reported in a one year old female with a similar phenotype comprising 
developmental delay, facial dysmorphism, cleft lip and palate and a thin corpus callosum.31 
For the two novel splice-variants we identified, we could not detect an aberrant transcript. 
This could be due to the skewed X-inactivation in the peripheral blood samples of these 





Clustering of the truncating variants in two distinct regions of the gene/protein points 
to specific effects. The very C-terminal variants leave all known functional domains intact, 
while the N-terminal splice variants in the splice acceptor of exon 8 would be expected to 
affect the LCEWAV and the Catenin-binding domain. Individuals 1 and 2 with these splice 
variants share particular clinical aspects such as skull shape and MRI abnormalities. Apart 
from that, the phenotype between individuals with C-terminal nonsense variants and N-
terminal splice variants is highly overlapping. We suspect a common loss-of-function 
consequence of the truncating variants rather than a dominant-negative effect. This would be 
in accordance with gnomAD constraint scores, indicating intolerance of MED12 towards loss-
of-function variants. As truncating variants in MED12 were mainly observed in females with a 
severe and syndromic phenotype, their functional consequence might be possibly more 
severe than the effect of most pathogenic missense variants. 
The phenotype in the 11 females with de novo missense variants appeared less 
specific in comparison, but was still homogenous with severe or profound ID in all but two 
individuals, frequent autistic features and lack or severe limitation of speech. Variable other 
anomalies included agenesis of corpus callosum, mild short stature, syndactyly, subtle facial 
dysmorphism and feeding difficulties. Similarly to previously reported missense variants 
found in males, the de novo missense variants identified in females in this study were 
distributed all over the protein. Previously, only two missense variants, p.(Glu172Gln)29 and 
p.(Arg521His),31 have been reported in females with comparable phenotypes. 
Pathogenic variants in MED12 are associated with various non-syndromic and 
syndromic NDDs in both males and females. Apart from shared intellectual disability, 
dysmorphic features such as blepharophimosis, brain anomalies such as agenesis or 
hypoplasia of corpus callosum or other morphological anomalies such as syndactyly overlap 
between both males and females but also within the male and within the female NDDs. In 
addition to the functional consequences (e.g. truncating versus missense variants) and the 
location of the variants, XCI patterns in females might also contribute to the variable 





contribute to the compensation of X-chromosomal variants in heterozygous females, thus 
preventing clinical manifestation. However, XCI patterns in previous reports did not correlate 
with presence or severity in female carriers of MED12 variants.14,15,17,25,29 While XCI skewing 
was demonstrated more frequently in 12 individuals with either truncating or missense 
variants, also random XCI was reported in four individuals, who did not present with a less or 
more severe phenotype. X-inactivation is a random transcriptional silencing process in 
gastrulation, where one of the two X chromosomes is inactivated. Afterwards this specific 
pattern is maintained in the daughter cells that all have the same maternal or paternal X- 
inactivated, often resulting in functional mosaicism with the mutant allele being active or 
inactive depending on the tissue. In blood or fibroblast cells of affected individuals, X-
inactivation was skewed, and only the wildtype allele could be detected, which would in 
principle point to a compensatory effect. Other tissues were not available. We therefore 
speculate that, in contrast to blood, the mutant allele might be active in progenitor brain cells 
and that this might underly the severe phenotype. Pigmentation anomalies can be suggestive 
for such a functional mosaicism.36 Such skin pigmentation anomalies were observed in at 
least three individuals in our cohort, and partial skin depigmentation was reported in one of 
the previously published female individuals.29 
In conclusion, we demonstrate that de novo missense and specific truncating variants 
in MED12 cause NDDs with variable abnormalities and dysmorphic features in females, 
partly overlapping with the previously known phenotypic spectrum from affected males. We 
speculate that “severity”, localization and functional consequences of the variants as well as 
XCI patterns in females might contribute to the clinical presentation and variability both 
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Fig. 1 - Graphical representation of de novo and inherited variants distributed across 
the known functional domains of the MED12 protein.  
Known ID‐associated missense variants in males are displayed below the protein scheme. 
Above are previously reported inherited frameshift,15 inherited17,25 and de novo29,30 missense, 
and de novo splice site31 variants in female individuals, together with the de novo variants in 
MED12 (NM_005120.2) identified in this study (in bold). MED12 domains; Med12: 
Transcription mediator complex subunit Med12. This subunit forms part of the kinase section 
of Mediator, which can negatively regulate the Gli3-dependent sonic hedgehog signaling 
pathway via its interaction with Gli3 within the RNA polymerase II. A complex is formed 
between Med12, Med13, CDK8 and CycC which is responsible for suppression of 
transcription.6 Med12-LCEWAV; Eukaryotic Mediator 12 subunit domain: The function of this 
region is not known, but there is a conserved sequence motif (LCEWAV). Med12-PQL; 
Eukaryotic Mediator 12 catenin-binding domain: β-catenin physically and functionally targets 
this PQL (proline-, glutamine-, leucine-rich) region of the Med12 subunit of Mediator to 






Fig. 2 – De novo canonical splice site variants in MED12.  
(A) Position of the variants (red circle) at the donor site of MED12 exon 9. Blue arrows 
represent primers used for analysis. (B, C) No effect on splicing is found on RT-PCR analysis 
of expression of MED12 in EBV-LCLs and fibroblast cell lines from patients and controls. 
One µg cycloheximide (CHX) per ml medium was added for four hours to inhibit nonsense-
mediated mRNA decay. (D, E) Minigene analysis shows that the canonical splice site 
variants induce skipping of exon 9 in the transcript containing the variant. This causes an 
ORF (open reading frame) change and the generation of a premature stop codon, 
p.(Val417Alafs*76). A non-transfected HEK293T cell line was used as control. 
 
Fig. 3 – Clinical appearance of female individuals with de novo variants in MED12.  
(A) Females with truncating variants presented with marked facial dysmorphism such as 
abnormal skull shape, low-set, posteriorly rotated ears, blepharophimosis, crowded teeth, 
retrognathia and variable other abnormalities such as syndactyly of fingers and/or toes. 
Individuals 1 and 2 with a splice site variant share a very prominent forehead and MRI 
anomalies such as partial agenesis of corpus callosum, enlarged ventricles and tectum and 
cerebellar vermis abnormalities. (B) In comparison, females with de novo missense variants 
presented with minor, but rather non-specific facial dysmorphisms and less frequently with 
other structural or morphological abnormalities such as syndactyly and clinodactyly of fingers 
and/or toes (I12, I11, I16) or brain abnormalities such as agenesis of corpus callosum (I8, 
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